ライフサイエンスコーパス: procalcitonin

1 aminoterminal portion of porcine prohormone procalcitonin.

2 ive protein and 0.78 (95% CI, 0.68-0.87) for procalcitonin.

3 -62%) and a specificity of 91% (76%-98%) for procalcitonin.

4 unts, C-reactive protein, interleukin-6, and procalcitonin.

5 adrenomedullin (0.70; 95% CI, 0.59-0.82) and procalcitonin (0.71; 95% CI, 0.60-0.83) compared with C-

6 adrenomedullin (0.81; 95% CI, 0.71-0.92) and procalcitonin (0.73; 95% CI, 0.60-0.85) each had a great

7 0.7-15.3] vs. 3.7 [0.6-9.8], p=.68) and peak procalcitonin (4.5 [1.0-22.9] vs. 5.0 [0.9-16.0], p=.91)

8 was associated with higher concentrations of procalcitonin, activation of the innate immune system (%

9 lator-associated pneumonia) and ineffective (procalcitonin algorithm for antibiotic deescalation) app

10 e assigned to receive antibiotics based on a procalcitonin algorithm or usual care by searching the C

11 Procalcitonin algorithms may reduce antibiotic use for a

12 Procalcitonin alone reliably discriminated between those

13 4.4% of the intensive care unit stays in the procalcitonin and control groups, respectively (p=.11).

14 The FAIM3:PLAC8 ratio outperformed plasma procalcitonin and IL-8 and IL-6 in discriminating betwee

15 Area under the curve for procalcitonin and interleukin-6, 24 hours after out-of-h

16 lmonary bypass increase in concentrations of procalcitonin and interleukin-8, but not of interleukin-

17 Both procalcitonin and lactate reliably discriminated between

18 The 116 amino acid prohormone procalcitonin and some of its component peptides (collec

19 -terminal pro-B-type natriuretic peptide and procalcitonin and the changes in hemodynamic variables a

20 to antimicrobial therapy, proadrenomedullin, procalcitonin, and C-reactive protein levels all signifi

21 thereafter, and the serum proadrenomedullin, procalcitonin, and C-reactive protein levels were measur

22 vels of high-sensitivity C-reactive protein, procalcitonin, and lipopolysaccharide at admission.

23 High expressions of the CALCA gene, procalcitonin, and NPCT were detected in the lung tissue

24 of NPCT decreased pulmonary levels of CALCA, procalcitonin, and NPCT; reduced lung inflammation and i

25 roadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

26 scular endothelial growth factor, protein C, procalcitonin, and proadrenomedullin were measured in ar

27 IL-1Ra), IL-8, IL-10, IL-18 binding protein, procalcitonin, and protein C in plasma did not differ be

28 macroglobulin, haptoglobin, serum amyloid P, procalcitonin, and tissue plasminogen activator) were si

29 N-terminal pro-B-type natriuretic peptide, procalcitonin, and waveform analysis of changes in strok

30 stigate the utility of proadrenomedullin and procalcitonin as diagnostic and prognostic biomarkers in

31 red to elucidate the source and action(s) of procalcitonin as well as its relationship to cytokine ac

32 Plasma procalcitonin at admission was significantly higher in c

33 Determine if procalcitonin at the time of initial rapid response team

34 Recent trials suggest procalcitonin-based guidelines can reduce antibiotic use

35 rences in the median serum concentrations of procalcitonin between patients with positive bronchoalve

36 patients with cancer, proadrenomedullin and procalcitonin both have a promising role in predicting b

37 Procalcitonin, but not high-sensitivity C-reactive prote

38 S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independ

39 Plasma levels of heparin-binding protein, procalcitonin, C-reactive protein, lactate, and leukocyt

40 lications were obtained using the MeSH terms procalcitonin, C-reactive protein, sepsis, and biologica

41 We evaluated the association between serum procalcitonin concentration at hospital admission with p

42 han those patients who died of heatstroke; a procalcitonin concentration of >0.5 ng/mL (>0.15 nmol/L)

43 The procalcitonin concentration subsequently increased to a

44 ents who survived had a significantly higher procalcitonin concentration than those patients who died

45 Median procalcitonin concentration was lower with viral pathoge

46 mly assigned to receive antibiotics based on procalcitonin concentrations (procalcitonin-guided group

47 s of interest was the relationship between a procalcitonin decrease of more than 80% from baseline to

48 2 hrs) was retrieved, frozen, and stored for procalcitonin determination.

49 Procalcitonin did not assist in the early diagnosis of s

50 The accuracy of C-reactive protein and procalcitonin did not differ at any postoperative day.

51 Procalcitonin did not differ between sepsis and "no seps

52 Finally, procalcitonin did not help improve concordance between t

53 all-cause mortality was two-fold higher when procalcitonin did not show a decrease of more than 80% f

54 Procalcitonin discriminated bacterial pathogens, includi

55 Procalcitonin discriminated between typical bacteria and

56 Procalcitonin dynamics were similar between surgical and

57 s were measured on day 1 and day 3 using the procalcitonin enzyme-linked fluorescent assay.

58 stration approved the blood infection marker procalcitonin for guiding antibiotic therapy in patients

59 C-reactive protein is more accurate than procalcitonin for the detection of infectious complicati

60 eactive protein was more discriminating than procalcitonin for the detection of intra-abdominal infec

61 The utility of procalcitonin for the diagnosis of infection in the crit

62 and includes topics such as the serum marker procalcitonin, gene expression profiling, matrix-assiste

63 r transfection of a chimeric cDNA encoding a procalcitonin-GIF fusion protein into the helper cell-de

64 selected subgroups only (C-reactive protein, procalcitonin, glucometer).

65 There were 258 patients in the procalcitonin group and 251 patients in the control grou

66 patients were randomized: 49 patients to the procalcitonin group and 45 patients to the C-reactive pr

67 fection was 7.0 (Q1-Q3, 6.0-8.5) days in the procalcitonin group and 6.0 (Q1-Q3, 5.0-7.0) days in the

68 Patients were randomized in two groups: the procalcitonin group and the C-reactive protein group.

69 nt of withheld treatment was observed in the procalcitonin group of patients classified by the intens

70 Treatment failure occurred in 398 procalcitonin group patients (19.1%) and in 466 control

71 The procalcitonin group was considered superior if the durat

72 groups: one using the procalcitonin results (procalcitonin group) and one being blinded to the procal

73 8 deaths in 2085 patients (5.7%) assigned to procalcitonin groups compared with 134 deaths in 2126 co

74 Procalcitonin guidance was also associated with a 2.4-da

75 Procalcitonin guidance was not associated with increased

76 ose per 100 intensive care unit days using a procalcitonin-guided approach.

77 otics based on procalcitonin concentrations (procalcitonin-guided group) or control.

78 tality at 30 days was significantly lower in procalcitonin-guided patients than in control patients (

79 in control patients (286 [9%] deaths in 3336 procalcitonin-guided patients vs 336 [10%] in 3372 contr

80 lled trials was designed to assess safety of procalcitonin-guided treatment in patients with acute re

81 Procalcitonin has been evaluated as a biochemical tool t

82 Procalcitonin has been evaluated in several studies with

83 Procalcitonin has emerged as the inflammatory marker mos

84 rker POCTs, including C-reactive protein and procalcitonin, has the potential to improve the clinical

85 halved the diagnostic error rate compared to procalcitonin in all tested cohorts and cohort combinati

86 significantly associated with elevations in procalcitonin in cohorts who were and were not infected

87 However, proadrenomedullin was superior to procalcitonin in predicting response in all febrile pati

88 ew guidelines, further delineate the role of procalcitonin in predicting UTI, and explore the role of

89 C-reactive protein was as useful as procalcitonin in reducing antibiotic use in a predominan

90 uracy of the infectious diagnosis when using procalcitonin in the intensive care unit and of the diag

91 edictive abilities of C-reactive protein and procalcitonin in the occurrence of IAIs after elective c

92 Procalcitonin is a biomarker used to monitor bacterial i

93 Procalcitonin is a reliable prognostic marker of septic

94 The change in procalcitonin level in patients with intensive care unit

95 probably viral etiology had the lowest peak procalcitonin levels (1.7 [25th-75th percentiles, 1.6-1.

96 interval, 1.01-1.31; p = .04) and increasing procalcitonin levels (adjusted odds ratio, 5.63; 95% con

97 (hazard ratio=1.23 [1.01-1.49]; p=0.04) and procalcitonin levels (hazard ratio=1.20 [1.03-1.39]; p=0

98 e care unit transfer had significantly lower procalcitonin levels (median 0.28 ng/mL [interquartile r

99 studies analyzing C-reactive protein and/or procalcitonin levels at postoperative days 2, 3, 4, and/

100 vely validate that the inability to decrease procalcitonin levels by more than 80% between baseline a

101 Procalcitonin levels for intensive care unit transfers f

102 Serum procalcitonin levels had poor diagnostic value in separa

103 Preliminary results suggest procalcitonin levels in patients at the time of initial

104 The procalcitonin levels of patients with noninfectious inte

105 shorter in those who had a decrease in their procalcitonin levels on day 3 from baseline compared wit

106 ardiac arrest (all p values<0.001), but only procalcitonin levels showed overall differences between

107 Procalcitonin levels showed wide dispersion.

108 Procalcitonin levels were measured daily for 10 days and

109 Serial serum procalcitonin levels were measured on day 1 and day 3 us

110 9% of the cases with confirmed infection had procalcitonin levels<0.25 microg/L.

111 Systematic reviews of procalcitonin, mannose-binding lectin and molecular ampl

112 However, serial measurements of serum procalcitonin may be helpful in predicting survival from

113 Procalcitonin measuring for the initiation of antimicrob

114 We investigated whether a set of biomarkers (procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-

115 0.96-0.99) in predicting sepsis but not for procalcitonin (not significant; 95% CI, 0.29-0.46).

116 edicting death with an odds ratio of 4.0 vs. procalcitonin (odds ratio 3.2), interleukin-6 (odds rati

117 in was also significantly more accurate than procalcitonin on the fourth postoperative day (areas und

118 curve for predicting favorable response than procalcitonin (p < 0.0001).

119 howed that proadrenomedullin (p = 0.005) and procalcitonin (p = 0.009) each had a better performance

120 roup and levels of interleukin-6 (p=0.25) or procalcitonin (p=0.85).

121 iated with increased concentrations of serum procalcitonin, particularly among survivors.

122 of C-reactive protein (CRP) (2-200 mug/mL), procalcitonin (PCT) (0.2-50 ng/mL), and interleukin 6 (I

123 infections with recent growing attention to procalcitonin (PCT) and pro-adrenomedullin (proADM).

124 as augmented by measuring the serum level of procalcitonin (PCT) as a marker of bacterial infection.

125 The procalcitonin (PCT) assay is an accurate screening test

126 Procalcitonin (PCT) has been shown to be a useful surrog

127 Procalcitonin (PCT) is increasingly utilized to determin

128 Procalcitonin (PCT) is synthesized by a large number of

129 European studies suggest that the serum procalcitonin (PCT) level may be used to guide antibioti

130 multicentric, observational study to test if Procalcitonin (PCT) might be an early and reliable marke

131 r expressed on myeloid cells-1 (sTREM-1) and procalcitonin (PCT) were assayed, and the expression of

132 n reaction, urinary antigen tests, and serum procalcitonin (PCT) were done in nearly all cases.

133 Procalcitonin (PCT), a marker of bacterial sepsis, may a

134 (EGOFET) was developed for the detection of procalcitonin (PCT), a sepsis marker.

135 T) device was developed for the detection of procalcitonin (PCT), a specific and early marker for sep

136 The role of procalcitonin (PCT), a widely used sepsis biomarker, in

137 cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6).

138 shed markers IL-6, C-reactive protein (CRP), procalcitonin (PCT), and soluble urokinase plasminogen a

139 Randomized trials support use of procalcitonin (PCT)-based algorithms to decrease duratio

140 dogenous peptide derived from the prohormone procalcitonin, plays a critical role in the development

141 The use of procalcitonin (ProCT) as a marker of several clinical co

142 y aims to investigate the levels of salivary procalcitonin (ProCT) in patients with different periodo

143 We investigated procalcitonin (ProCT) levels in the serum and saliva of

144 strates, for the first time, the presence of procalcitonin (ProCT), an established serum marker of in

145 Procalcitonin (ProCT), the precursor to the calcitonin h

146 Widespread implementation of procalcitonin protocols in patients with acute respirato

147 Procalcitonin reacted to LPS insult late.

148 Amino-prohormone procalcitonin-reactive antiserum administration resulted

149 lcitonin group) and one being blinded to the procalcitonin results (control group).

150 re randomized into two groups: one using the procalcitonin results (procalcitonin group) and one bein

151 Procalcitonin seems not to have added value as compared

152 Procalcitonin serum level was obtained for all consecuti

153 development of SIRS should be investigated; procalcitonin serum levels can help to identify patients

154 en viral and bacterial pathogens, but higher procalcitonin strongly correlated with increased probabi

155 ion layer) served to selectively capture the procalcitonin target analyte.

156 Procalcitonin, the precursor peptide of calcitonin, has

157 A procalcitonin threshold of 0.1 ng/mL resulted in 80.9% (

158 No procalcitonin threshold perfectly discriminated between

159 The ability of procalcitonin to differentiate between certain or probab

160 However, the accuracy of procalcitonin to discriminate between viral and bacteria

161 Accuracy of procalcitonin to discriminate between viral and bacteria

162 spiratory tract infection, is measurement of procalcitonin to guide antibiotic prescriptions associat

163 INTERPRETATION: Use of procalcitonin to guide antibiotic treatment in patients

164 Use of procalcitonin to guide initiation and duration of antibi

165 The measurement of procalcitonin to guide initiation and duration of antibi

166 C-reactive protein (CRP), procalcitonin, tumor necrosis factor alpha, interleukin

167 s in which no infection was confirmed, had a procalcitonin value>1microg/L and 14.9% of the cases wit

168 rgical infected cohorts had similar baseline procalcitonin values (3.0 [0.7-15.3] vs. 3.7 [0.6-9.8],

169 Shock had an association with higher procalcitonin values independent of the presence of infe

170 Herein, we report procalcitonin values relative to baseline patient charac

171 at admission had a trend toward higher peak procalcitonin values than did those whose infection deve

172 Trends in differences in procalcitonin values were seen in patients who had incid

173 The mean serum procalcitonin was elevated 20-fold on admission in patie

174 Procalcitonin was measured daily over the first 5 days.

175 Interestingly, procalcitonin was only significantly increased in patien

176 We sought to evaluate whether procalcitonin was superior to C-reactive protein in guid

177 A rapid immunochemical assay for serum procalcitonin was utilized.

178 inflammation, assessed by interleukin-6 and procalcitonin, was independently associated with increas

179 tor, vascular endothelial growth factor, and procalcitonin were elevated but not differentially affec

180 C-reactive protein and procalcitonin were measured daily until the fourth posto

181 a, interferon-gamma, C-reactive protein, and procalcitonin were measured.

182 ukin-8, transforming growth factor-beta, and procalcitonin were subsequently analyzed using enzyme-li

183 his study addressed the correlation of serum procalcitonin with the course of classic (nonexertional)